Browsing by Author "Erkuran, Handan Ozek"

Now showing 1 - 2 of 2

Citation - WoS: 6
Citation - Scopus: 7
Genetic Imaging Study With [tc-(99m)] Trodat-1 Spect in Adolescents With Adhd Using Oros-Methylphenidate
(Pergamon-Elsevier Science Ltd, 2018) Akay, Aynur Pekcanlar; Kaya, Gamze Capa; Kose, Samet; Yazicioglu, Cigdem Eresen; Erkuran, Handan Ozek; Guney, Sevay Alsen; Oguz, Kaya
Aim: To examine theeffects on the brain of 2-month treatment withamethylphenidate extended-release formulation (OROS-MPH) using [Tc-(99m)] TRODAT-1SPECT in a sample of treatment-naive adolescents with Attention Deficit/Hyperactivity Disorder (ADHD). In addition, to assess whether risk alleles (homozygosity for 10-repeat allele at the DAT1 gene were associated with alterations in striatal DAT availability. Methods: Twenty adolescents with ADHD underwent brain single-photon emission computed tomography (SPECT) scans with [Tc-(99m)] TRODAT-1 at baseline and two months after starting OROS-MPH treatment with dosages up to 1 mg/kg/day. Severity of illness was estimated using the Clinical Global Impression Scale (CGI-S) and DuPaul ADHD Rating Scale-Clinician version (ARS) before treatment,1 month and 2 months after initiating OROS-MPH treatment. Results: Decreased DAT availability was found in both the right caudate (pretreatment DAT binding: 224.76 +/- 33.77, post-treatment DAT binding: 208.86 +/- 28.75, p = 0.02) and right putamen (pre-treatment DAT binding: 314.41 +/- 55.24, post-treatment DAT binding: 285.66 +/- 39.20, p = 0.05) in adolescents with ADHD receiving OROS-MPH treatment. Adolescents with ADHD who showed a robust response to OROS-MPH (n = 7) had significantly greater reduction of DAT density in the right putamen than adolescents who showed less robust response to OROS-MPH (n = 13) (p = 0.02). However, between-group differences by treatment responses were not related with DAT density in the right caudate. Risk alleles (homozygosity for the 10-repeat allele of DAT1 gene) in the DAT1 gene were not associated with alterations in striatal DAT availability. Conclusion: Two months of OROS-MPH treatment decreased DAT availability in both the right caudate and putamen. Adolescents with ADHD who showed a robust response to OROS-MPH had greater reduction of DAT density in the right putamen. However,our findings did not support an association between homozygosity for a 10-repeat allele in the DAT1 gene and DAT density, assessedusing[Tc-(99m)] TRODAT-1SPECT.
L-Carnitine Use as a Trigger for the Onset of Kleine-Levin Syndrome: a Case Presentation
(Klinik Psikiyatri Dergisi, 2022) Yaylaci, Ferhat; Kucuk, Onder; Erkuran, Handan Ozek
Kleine- Levin Syndrome (KLS) is a rare phenomenon characterized by repeating episodes of hypersomnia, cognitive and behavioral impairments, compulsive eating behavior, and hypersexuality. Postinfectious processes, alcohol consumption, sleep deprivation, psychological stress, getting vaccinated, head injury and genetic factors have been identified possible etiological factors. Abnormal metabolism of serotonin and dopamine have also been reported. Alcohol and cannabis have been listed among triggering factors. With its role as a mediator required to transport long-chain fatty acids to mitochondrial matrix and its contributions in increasing oxidation of fatty acids, L-carnitine helps to produce more energy from burning fat while maintaining economic use of muscle glycogen stocks. Animal studies have shown a continous increase in dopamine discharge within nucleus accumbens via acetyl L-carnitine application. Carnitine supplementation is known to cause increased dopamine levels within cortical, hippocampal and striatal regions of the rat brain. One case report reported severe psychotic symptoms in a patient with bipolar disorder, following acetyl L-carnitine use. In this case presentation, we have aimed to present clinical course of an adolescent using L-carnitine for ergogenic support, as a possible trigger for the onset of a KLS episode.